Collegium Pharmaceutical (COLL) FY2020 results: revenue $310 million, up 4.5% on the year
Collegium Pharmaceutical, Inc. (COLL) reported revenue of $310 million for fiscal 2020, the year ended 31 December 2020, up 4.5% on the year before. Net income was $27 million, and diluted earnings per share $0.76. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2021.
Revenue
$310 million
+4.5% on the year
FY2016FY2020
Operating margin
18.1%
-8.0% a year earlier
FY2016FY2020
Net income
$27 million
FY2016FY2020
Diluted EPS
$0.76
FY2016FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
310
297
280
+4.5%
Cost of revenue
130
194
166
-32.8%
Gross profit
180
103
115
+74.5%
Gross margin
58.0%
34.7%
40.9%
Research and development
9.8
10.3
8.7
-5.5%
Selling, general and administrative
114
116
127
-2.2%
Operating income
56.2
-23.7
-20.7
Operating margin
18.1%
-8.0%
-7.4%
Interest expense
28.9
0.9
20.1
+3,077.3%
Pre-tax income
27.6
-22.7
-39.1
Income tax
0.8
0.0
n/a
Effective tax rate
3.0%
n/a
n/a
Net income
26.8
-22.7
-39.1
Net margin
8.6%
-7.7%
-14.0%
Diluted EPS
$0.76
-$0.68
-$1.19
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
93.9
27.8
169
+238.1%
Capital expenditure
5.5
6.4
5.5
-13.9%
Free cash flow
88.4
21.3
164
+314.1%
Free cash flow margin
28.5%
7.2%
58.5%
Cash from investing
-374
-6.4
-24.4
Cash from financing
286
2.0
-117
+13,936.0%
Depreciation and amortisation
61.5
0.7
1.1
+8,320.0%
Share-based compensation
21.9
16.5
13.8
+32.6%
Diluted shares, weighted
35m
33m
33m
+5.1%
Shares outstanding at period end
35m
34m
33m
+2.8%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
186
87.4
91.6
+112.8%
Debt
257
11.5
11.5
+2,135.6%
Operating lease liabilities
8.8
9.4
n/a
-7.1%
Other liabilities
192
198
188
-3.0%
Total liabilities and equity
644
306
291
+110.2%
Fixed assets
19.0
11.9
9.3
+60.2%
Intangible assets
336
29.5
44.3
+1,038.5%
Cash and equivalents
174
170
147
+2.4%
Receivables
83.3
73.0
77.9
+14.2%
Inventory
15.6
9.6
7.8
+61.9%
Other assets
15.9
12.3
5.3
+28.9%
Total assets
644
306
291
+110.2%
10-K for the year ended 31 December 2020, filed 25 February 2021: the filing.